Epistem announces three-year collaboration with GSK

Will apply RND-Amp technology to fibrosis research

Epistem, an oncology and biomarker research services company based in Manchester, UK, has entered into a three-year biomarker collaboration with GlaxoSmithKline in the field of fibrosis research. No financial details have been released.

The collaboration will focus on identifying key characteristics of diseased fibrotic tissue on which Epistem will apply its RNA-Amp technology to facilitate building an in-depth understanding of the disease.

RNA-Amp amplification technology provides gene expression information from small tissue samples and low of numbers of cells, in addition to laser captured microdissected (LCM) samples.

Epistem also brings its cell and molecular biology expertise to the collaboration.